A Study to Investigate the Safety and Efficacy of GB1211 (a Galectin-3 Inhibitor) in Combination With Atezolizumab in Patients With Non-Small Cell Lung Cancer (NSCLC).
Study Details
Study Description
Brief Summary
This study is an open label study followed by a randomised, double-blind, placebo-controlled, parallel group and an extension study to investigate the safety and efficacy of GB1211 (a galectin-3 inhibitor) in combination with atezolizumab in patients with Non-Small Cell Lung Cancer (NSCLC).
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 1/Phase 2 |
Detailed Description
The study will be carried out in three parts: The core study is comprised of part A (dose finding and safety) and part B (efficacy and safety). Part C is an extension phase of the core study to collect long-term safety data.
In part A of the study, open-label sentinel dosing will be undertaken to assess safety and tolerability of GB1211 at 200 mg BID and 400 mg BID in combination with atezolizumab including 4 patients in each dose cohort. Patients enrolled in part A may continue treatment with 200 mg GB1211 BID or 400 mg GB1211 BID and atezolizumab for 12 weeks, after which the patients will be offered treatment in the part C study, if they have achieved clinical benefit as best response during the first 12 weeks of treatment (SD or better response according to RECIST 1.1).
In part B of the study, patients will randomised (1:1) for blinded treatment to receive either GB1211 (200 or 400 mg BID to be selected from part A) or placebo, in addition to atezolizumab, for 12 weeks, after which the patients will be offered treatment in part C, if they have achieved clinical benefit as best response during the first 12 weeks of treatment (SD or better response according to RECIST 1.1).
In part C, this treatment will be blinded until part B has been unblinded. After unblinding, patients will continue to receive the same treatment they had received in part B: GB1211 and atezolizumab or atezolizumab only (no placebo) if they experience continued benefit from treatment. The patients will be treated until disease progression or unacceptable toxicity.
After the end of the study treatment all patients will be followed 4 weeks for safety, regardless of the study part in which the last study treatment was given.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Part A - GB1211 200 mg and 400 mg BID in combination with atezolizumab. Part A of the study, open-label sentinel dosing will be undertaken to assess safety and tolerability of GB1211 at 200 mg and 400 mg BID in combination with atezolizumab. |
Drug: GB1211
GB1211 is a galectin 3 inhibitor an orally available small molecular anti-fibrotic. It is administered orally twice a day.
Drug: Atezolizumab
Atezolizumab is an PD-L1 inhibitor administered as an intravenous infusion every three weeks at a dose of 1200mg
|
| Experimental: Part B - GB1211 (200 or 400 mg BID) or Placebo in addition to atezolizumab Part B of the study, GB1211 (200 or 400 mg BID to be selected from part A) in addition to atezolizumab, for 12 weeks |
Drug: GB1211
GB1211 is a galectin 3 inhibitor an orally available small molecular anti-fibrotic. It is administered orally twice a day.
Drug: Placebo
Placebo is administered orally twice a day.
Drug: Atezolizumab
Atezolizumab is an PD-L1 inhibitor administered as an intravenous infusion every three weeks at a dose of 1200mg
|
| Experimental: Part C - Extension of GB1211 (200 or 400 mg BID) or Placebo in addition to atezolizumab Extension of GB1211 in addition to atezolizumab until part B has been unblinded. Extension of placebo in addition to atezolizumab until part B has been unblinded |
Drug: GB1211
GB1211 is a galectin 3 inhibitor an orally available small molecular anti-fibrotic. It is administered orally twice a day.
Drug: Placebo
Placebo is administered orally twice a day.
Drug: Atezolizumab
Atezolizumab is an PD-L1 inhibitor administered as an intravenous infusion every three weeks at a dose of 1200mg
|
Outcome Measures
Primary Outcome Measures
- PART A - To assess the safety and tolerability of GB1211 in combination with atezolizumab. [3 weeks]
Incidence and severity of adverse events as reported by investigators.
- PART B - To assess the safety and tolerability of GB1211 in combination with atezolizumab compared to atezolizumab and placebo [12 weeks]
Incidence and severity of adverse events
- Part B -To assess the efficacy of GB1211 compared to placebo by measuring the change of the longest diameters of target lesions at week 12. [12 weeks]
Independent central review of CT, PET/CT or MRI scan according to RECIST 1.1
- Part C - To assess the long-term safety and tolerability of GB1211 in combination with atezolizumab compared to atezolizumab alone. [12 - 40 weeks]
Incidence and severity of adverse events.
Secondary Outcome Measures
- Part A -To determine the recommended dose (200 mg BID or 400 mg BID) of GB1211 in combination with atezolizumab. [3 weeks]
Incidence and severity of adverse events as reported by investigators.
- Part A and B - To assess response rate according to RECIST v1.1 of GB1211 versus placebo in combination with atezolizumab. [12 weeks]
Independent central review of CT, PET/CT or MRI scan according to RECIST 1.1
- To measure the maximum plasma concentration of GB1211 (Cmax) [12 weeks]
Plasma concentrations of GB1211 [Time Frame: Part A - Cycle 1 Day 1: pre-dose, 2, 4, 6, 8, 12 hours post-dose; Cycle 2 Day 1: pre-dose, 2, 4, 6, 8, 12 hours post-dose; Cycle 3 Day 1: pre-dose, between 2 and 4 hours post-dose, between 4 and 8 hours post-dose; End of Treatment: pre-dose, between 2 and 4 hours post-dose, between 4 and 8 hours post-dose. Part B - Cycle 1 Day 1: pre-dose, between 2 and 4 hours post-dose, between 4 and 8 hours post-dose; Cycle 2 Day 1: pre-dose; Cycle 3 Day 1: pre-dose; End of Treatment: pre-dose, between 2 and 4 hours post-dose, between 4 and 8 hours post-dose] for the calculation of pharmacokinetic parameter maximum plasma concentration (Cmax) of GB1211
- To measure the time of maximum plasma concentration of GB1211 (Tmax) [12 weeks]
Plasma concentrations of GB1211 [Time Frame: Part A - Cycle 1 Day 1: pre-dose, 2, 4, 6, 8, 12 hours post-dose; Cycle 2 Day 1: pre-dose, 2, 4, 6, 8, 12 hours post-dose; Cycle 3 Day 1: pre-dose, between 2 and 4 hours post-dose, between 4 and 8 hours post-dose; End of Treatment: pre-dose, between 2 and 4 hours post-dose, between 4 and 8 hours post-dose. Part B - Cycle 1 Day 1: pre-dose, between 2 and 4 hours post-dose, between 4 and 8 hours post-dose; Cycle 2 Day 1: pre-dose; Cycle 3 Day 1: pre-dose; End of Treatment: pre-dose, between 2 and 4 hours post-dose, between 4 and 8 hours post-dose] for the calculation of pharmacokinetic parameter time of the maximum plasma concentration (Tmax) of GB1211
- To measure the area under the concentration-time curve of GB1211 (AUC) [12 weeks]
Plasma concentrations of GB1211 [Time Frame: Part A - Cycle 1 Day 1: pre-dose, 2, 4, 6, 8, 12 hours post-dose; Cycle 2 Day 1: pre-dose, 2, 4, 6, 8, 12 hours post-dose; Cycle 3 Day 1: pre-dose, between 2 and 4 hours post-dose, between 4 and 8 hours post-dose; End of Treatment: pre-dose, between 2 and 4 hours post-dose, between 4 and 8 hours post-dose. Part B - Cycle 1 Day 1: pre-dose, between 2 and 4 hours post-dose, between 4 and 8 hours post-dose; Cycle 2 Day 1: pre-dose; Cycle 3 Day 1: pre-dose; End of Treatment: pre-dose, between 2 and 4 hours post-dose, between 4 and 8 hours post-dose] for the calculation of pharmacokinetic parameter area under the plasma concentration versus time curve (AUC) of GB1211
- Part C - To assess response rates for those patients who enter the study with at least Stable Disease as best response. [12 - 40 weeks]
Independent central review of CT, PET/CT or MRI scan according to RECIST 1.1
Eligibility Criteria
Criteria
Inclusion criteria:
Patients must meet the following criteria for study entry:
-
Must be ≥ 18 years of age at the time of signing the Informed Consent Form (ICF).
-
Must provide signed ICF.
-
Must have the ability to comply with the study protocol, in the investigator's judgment.
-
Women of childbearing potential must agree to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures and agree to refrain from donating eggs.
-
Men must agree to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures and agree to refrain from donating sperm.
-
Diagnosed NSCLC with adenocarcinoma and its variants according to the 2015 WHO classification (Travis et al. 2015).
-
Measurable disease, as defined by RECIST v1.1.
-
Have histologically or cytologically confirmed advanced or metastatic NSCLC defined as:
Stage IIIB that either progressed after curative therapy (chemoradiation and/or surgery) or is not candidate to curative therapy, or Stage IV metastatic disease (de novo or distant relapse) [According to UICC TNM edition 8].
-
Expressing PD-L1 on at least 50% of tumour cells, as determined through use of the Dako PD-L1 IHC 22C3 pharmDx assay or the Ventana PD-L1 IHC SP263 assay.
-
Agree to have a tumour biopsy that is eligible for Gal-3 expression evaluation before the first study drug dose.
-
Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.
-
Have not received prior systemic chemotherapy for the treatment of recurrent, advanced or metastatic disease, treatment with chemotherapy and/or radiation as part of neoadjuvant/adjuvant therapy is allowed as long as completed at least 4 weeks prior to diagnosis of recurrent advanced or metastatic disease.
-
Patients must not have received immune checkpoint inhibitors (ICI) previously.
-
Must be eligible for atezolizumab at 1200 mg every 3 weeks as defined in the atezolizumab product label.
-
Patients receiving therapeutic anticoagulation must be on stable regimen.
-
Adequate haematologic and end-organ function, defined by the following laboratory test results, obtained within 14 days prior to initiation of study treatment:
-
Absolute neutrophil count (ANC) ≥1.5 x 109/L (1500/µL) without granulocyte colony-stimulating factor support.
-
Lymphocyte count ≥0.5 x 109/L (500/µL).
-
Platelet count ≥ 100 x 109/L (100,000/µL) without transfusion.
-
Haemoglobin ≥ 90 g/L (9 g/dL). Patients may be transfused to meet this criterion.
-
Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP) ≤ 2.5 x upper limit of normal (ULN), with the following exceptions:
-
Patients with documented liver metastases: AST and ALT ≤ 5 x ULN.
-
Patients with documented liver or bone metastases: ALP ≤ 5 x ULN.
-
Total bilirubin ≤ 1.5 x ULN with the following exception:
Patients with known Gilbert disease: total bilirubin ≤ 3 x ULN.
-
Creatinine clearance ≥50 mL/min (calculated using the Cockcroft-Gault formula).
-
Albumin ≥25 g/L (2.5 g/dL).
-
For patients not receiving therapeutic anticoagulation: INR and a PTT ≤1.5 x ULN.
Exclusion criteria:
Patients who meet any of the following criteria will be excluded from study participation.
-
Known contraindications for treatment with PD-1/PD-L1 inhibitors.
-
Patients with known hypersensitivity to GB1211 or any of the excipients.
-
Women who are pregnant or breast-feeding or intending to become pregnant during study treatment or within 9 months after the final dose of study treatment.
-
Women of childbearing potential without a negative serum pregnancy test result within 14 days prior to initiation of study treatment.
-
Women of child-bearing potential or men who are unwilling to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures during the study, and do not agree to refrain from donating sperm or egg cells from the first dose of study drug up to 9 months after the last dose of study drug.
-
Patients with adenosquamous carcinomas, defined as tumours composed of more than 10 percent malignant glandular and squamous components.
-
Presence of oncogenes EGFR (exon 19 deletions, pL858R point mutation in exon 21), ALK rearrangements, RET rearrangements, or ROS1 mutation.
-
Hepatic impairment of Child Pugh B or C.
-
Patients with active hepatitis B (chronic or acute; defined as having a positive hepatitis B surface antigen [HBsAg] test result at screening) and/or hepatitis C virus (HCV).
-
Patients with active human immunodeficiency virus (HIV).
-
Patients who are positive for coronavirus disease 2019 (COVID-19) by naso-pharyngeal swab test.
-
Active or history of autoimmune disease or immune deficiency.
-
Patients with severe infection within 4 weeks prior to initiation of study treatment.
-
Patients with acute neurological events (e.g., intracranial or subarachnoid haemorrhage, stroke, intracranial trauma) within 6 months of inclusion.
-
Patients with symptomatic, untreated, or actively progressing central nervous system (CNS) metastases.
-
No tumour specimen, obtained in the last 6 months, is available to analyse galectin expression and it is not feasible to obtain a new specimen (note: cytology samples are admissible).
-
Patients with past medical history or any evidence of clinically active interstitial lung disease.
-
Uncontrolled significant pleural effusion.
-
History of non-infectious pneumonitis that required steroids or current pneumonitis.
-
Patients with significant cardiovascular disease such as but not limited to unstable arrhythmia requiring treatment, myocardial infarction, ischaemia, transient ischemic attack (TIA), congestive heart failure New York Heart Association (NYHA) class II-IV, left ventricular hypertrophy, cardiomyopathy, conduction disorder, uncontrolled hypertension, bradycardia, LVEF< 40% or a QT/QTc interval > 470 ms.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Centre Georges Grancois Leclerc | Dijon | France | 21000 | |
| 2 | Hôpital Arnaud de Villeneuve | Montpellier | France | 34295 | |
| 3 | CHRU | Tours | France | 37044 | |
| 4 | Hospital Universitario y Politécnico La Fe | Valencia | València | Spain | 46026 |
| 5 | Hospital Universitario 12 de Octubre | Madrid | Spain | 28041 |
Sponsors and Collaborators
- Galecto Biotech AB
- Linical Europe GmbH
- Hoffmann-La Roche
Investigators
- Principal Investigator: Francois Ghiringhelli, MD, Centre Georges Grancois Leclerc, Dijon
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- GALLANT-1